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Abstract
Background: Glioblastoma is a complex multifactorial disorder that has swift and devastating consequences. Few
genes have been consistently identified as prognostic biomarkers of glioblastoma survival. The goal of this study
was to identify general and clinical-dependent biomarker genes and biological processes of three complementary
events: lifetime, overall and progression-free glioblastoma survival.
Methods: A novel analytical strategy was developed to identify general associations between the biomarkers and
glioblastoma, and associations that depend on cohort groups, such as race, gender, and therapy. Gene network
inference, cross-validation and functional analyses further supported the identified biomarkers.
Results: A total of 61, 47 and 60 gene expression profiles were significantly associated with lifetime, overall, and
progression-free survival, respectively. The vast majority of these genes have been previously reported to be
associated with glioblastoma (35, 24, and 35 genes, respectively) or with other cancers (10, 19, and 15 genes,
respectively) and the rest (16, 4, and 10 genes, respectively) are novel associations. Pik3r1, E2f3, Akr1c3, Csf1, Jag2,
Plcg1, Rpl37a, Sod2, Topors, Hras, Mdm2, Camk2g, Fstl1, Il13ra1, Mtap and Tp53 were associated with multiple survival
events.
Most genes (from 90 to 96%) were associated with survival in a general or cohort-independent manner and thus
the same trend is observed across all clinical levels studied. The most extreme associations between profiles and
survival were observed for Syne1, Pdcd4, Ighg1, Tgfa, Pla2g7, and Paics. Several genes were found to have a cohort-
dependent association with survival and these associations are the basis for individualized prognostic and gene-
based therapies. C2, Egfr, Prkcb, Igf2bp3, and Gdf10 had gender-dependent associations; Sox10, Rps20, Rab31, and
Vav3 had race-dependent associations; Chi3l1, Prkcb, Polr2d, and Apool had therapy-dependent associations.
Biological processes associated glioblastoma survival included morphogenesis, cell cycle, aging, response to stimuli,
and programmed cell death.
Conclusions: Known biomarkers of glioblastoma survival were confirmed, and new general and clinical-dependent
gene profiles were uncovered. The comparison of biomarkers across glioblastoma phases and functional analyses
offered insights into the role of genes. These findings support the development of more accurate and personalized
prognostic tools and gene-based therapies that improve the survival and quality of life of individuals afflicted by
glioblastoma multiforme.
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Glioblastoma multiforme (glioblastoma, World Health
Organization grade IV astrocytoma) accounts for 15%-
20% of all intracranial tumors and 50% of all brain
malignancies [1]. This aggressive malignant type of pri-
mary brain tumor has swift and devastating conse-
quences resulting in a median survival after diagnosis of
one year [2,3,2]. Primary glioblastoma has a higher inci-
dence in Caucasian men than in other racial and gender
groups [4] although these differences may be con-
founded with differences in access to health care or
diagnostic practices [5]. Also, the variation in response
to glioblastoma therapies and similar median survival
across therapies has prevented the identification of a
therapy or therapies directly associated with glioblas-
toma survival [6-9].
Numerous studies have proposed biomarker genes
that can be used to accurately predict the clinical course
of glioblastoma [10-16]. Although some genes have been
associated with the presence of glioblastoma, few have
been identified as prognostic biomarkers of glioblastoma
survival and fewer have been confirmed in independent
reports. The limited reproducibility of gene-glioblastoma
associations may be, in part, due to limited or no con-
sideration of the clinical characteristics of the indivi-
duals studied, such as gender and therapy subject
[17-19]. Another reason for the lack of confirmation of
biomarker genes of glioblastoma may be the considera-
tion of the association between glioblastoma and indivi-
dual genes independently, although multiple genes
acting in unison are known to influence this disease.
Statistical reasons for this lack of confirmation include
the analysis of gene expression levels in glioblastoma
versus non-glioblastoma samples instead of analyzing
survival, and the failure to correctly model the censored
nature of the observations that may not exhibit the pro-
gression or death event by the end of the period consid-
ered. For example, The Cancer Genome Atlas Research
Network (TCGA [20]) identified gene expression aberra-
tions among the 206 glioblastoma cases considered but
did not consider the age at glioblastoma death or pro-
gression, nor the clinical characteristics of the indivi-
duals studied.
The goal of this study was to identify general and clin-
ical-dependent biomarker genes and biological processes
of three complementary events: lifetime, overall and pro-
gression-free glioblastoma survival. A novel analytical
strategy was developed to identify general and cohort-
dependent associations between the biomarkers and the
three glioblastoma events. Cross-validation and func-
tional analysis further supported the identified biomar-
kers. The identification of gene biomarkers of
glioblastoma survival supports the efficient follow-up
studies using in vitro and in vivo experiments and
augments the molecular toolbox that can be used to
classify patients across and within cohort groups with
respect to prognosis and the development of targeted
treatments.
Methods
Data
Clinical and gene expression information from 320 indi-
viduals diagnosed with glioblastoma was obtained from
the TCGA repository (September 2009 data freeze [21].
Protocols for specimen preparation and gene expression
measurements are described in detail in the report by
The Cancer Genome Atlas Research Network [20].
Briefly, a retrospective search in glioblastoma sample
banks identified newly diagnosed glioblastoma cases
based on surgical pathology reports and clinical records.
Only samples that had demographic, clinical and patho-
logical information, a minimum of 80% tumor nuclei,
and a maximum of 50% necrosis, qualified for gene
expression analyses.
The data included glioblastoma diagnostic and death
records between the years 1989 and 2009. Clinical fac-
tors used to classify individuals into cohort groups were
Gender (Male or Female), Race (White Caucasian or
Other), Therapy received (R = radiation alone; CRnoT =
chemo, radiation and not targeted therapy plus other
therapy if present; CRT = chemo plus radiation and tar-
geted therapy only; Other = any other combination of
radiation, chemo, targeted, immune and hormonal ther-
apy; or None = no therapy), and detection of glioblas-
toma progression or recurrence (ProgRec - Yes/No).
Three glioblastoma time-to-event variables were con-
sidered: lifetime survival (encompassing the period from
birth to death), overall or post-diagnosis survival
(encompassing the period from glioblastoma diagnosis
to death) and post-diagnosis progression-free survival
(encompassing the period from glioblastoma diagnosis
to progression of glioblastoma or to recurrence of glio-
blastoma). The distribution of the observations among
the levels of the clinical or cohort variables is presented
in Table 1. There were 287 individuals with sufficient
survival information for analysis. Three individuals were
excluded from the progression-free survival analysis
because of inconsistency in the dates for diagnosis and
progression or recurrence.
Gene expression measurements were obtained using
the Affymetrix HT HG-U133A platform, comprising
22,277 probe sets. The gene expression measurements
were obtained in ten experimental batches, in which the
percentage of individuals per batch ranged from 4.35%
to 21.25%. For samples with multiple gene expression
measurements, the correlation between measurements
across microarrays was higher than 0.98 and, thus, the
average expression was used to represent the sample.
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ized using quantile normalization and GC-RMA [22]
approaches implemented in Beehive [23].
In addition to detecting genes in the microarray plat-
form associated with the glioblastoma survival, particu-
lar attention was given to genes known to be associated
with glioblastoma and the association detected in this
study. A list, including 123 genes known to be asso-
ciated with glioblastoma were identified from the litera-
ture [20,24-27] and 51 genes in the KEGG glioma
pathway [28], was compiled (see Additional file 1).
Statistical Analysis
A five-step approach was used to reduce the dimension-
ality of the data set caused by the large number of
probes and few records of the individuals in this experi-
ment. First, a Cox proportional hazards survival analysis
[29] was undertaken for each non-control probe in the
microarray platform. The model included all the clinical
variables with the profile of only one probe. This step
allowed the selection of probes associated with each of
the three survival variables at P-value < 0.01. This mild
threshold was used to minimize the chances of false
negative associations and evaluate in subsequent steps
probes with strong or moderate associations with glio-
blastoma per se. The number of probes identified for
lifetime survival, overall, and progression-free survival
was 963, 839, and 1048 respectively. Second, for each
one of the three glioblastoma time-to-event variables,
the clinical variables and all remaining probes identified
in the first step were included simultaneously in a Cox
survival model. In this manner, the clinical variables
were fixed component of the model and the probes
associated with the survival variables were selected using
a combination of forward and stepwise model selection
methods. The forward selection method was used to
add one probe at a time to the model containing the
clinical variables using a significance level for entry of
30%. In the complementary stepwise selection method,
the inclusion of probes followed the same rules as in the
forward method but a probe only remained in the
model if its P-value was lower than the significance
levels for stay of 10%. Since these two selection methods
could result in different models, a second stepwise selec-
tion was performed using the significant probes. This
step allowed identifying broad or general associations
between probe profiles and glioblastoma survival. Third,
the interaction between the remaining probes and clini-
cal variables was evaluated using the stepwise approach.
This step permitted the detection of clinical or cohort-
dependent associations between probe profiles and glio-
blastoma survival. The fourth stage of our approach
aimed to select the significant probes from our list of
174 known genes associated with glioblastoma (see
Additional file 1) fitting the probes and interaction with
the clinical variables using the stepwise selection
method. The consideration of the known probes alone
aimed at minimizing the potential masking of associa-
tions by other probes in the model. Similarly to the pre-
vious step, in the final step the probes identified from
both sets of analyses were combined and further stream-
lined using the stepwise method. This final step allowed
Table 1 Median length of the hazard period and (relative) frequency of the individuals across clinical cohort levels
Lifetime survival (n = 287)
1 Overall survival (n = 287)
2 Progression-free survival (n = 284)
2
Censored (0.12) (0.12) (0.23)
Lifetime 59.2 13.1 6.5
Gender
Male 58.8 (0.63) 13.6 (0.63) 6.6 (0.63)
Female 61.1 (0.37) 12.1 (0.37) 6.4 (0.37)
Race
White 59.7 (0.77) 13.1 (0.77) 6.8 (0.77)
Other 57.7 (0.23) 12.6 (0.23) 5.3 (0.23)
Therapy
CRnoT 57.7 (0.40) 15.7 (0.40) 8.0 (0.34)
R 60.7 (0.35) 12.3 (0.35) 5.3 (0.41)
CRT 53.4 (0.10) 15.4 (0.10) 6.8 (0.10)
Other 64.8 (0.08) 14.2 (0.08) 7.9 (0.08)
None 70.5 (0.07) 2.9 (0.07) 1.4 (0.07)
ProgRec
Yes 57.6 (0.77) 15.1 (0.77) - (0.77)
No 64.8 (0.23) 5.9 (0.23) - (0.23)
1 expressed in years;
2 expressed in months.
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previous studies as well as the identification of novel
associations. With respect to P-value threshold selection
at each stage, a lenient first-stage threshold was used to
c a p t u r em o s tt r u ep o s i t i v ea s s o c i a t i o n sa tt h ee x p e n s eo f
some false positives. The more stringent threshold used
in the subsequent steps and repeated selection process
minimized the number of false positives remaining in the
index. Thus, this approach would have the same effect
than reducing the threshold in the first step with the
added benefit of minimizing the loss of true positives.
Likewise, extending the first-stage threshold would have
resulted in more false positives being considered in the
second stage and higher risks of overparameterization.
In addition to a P-value, each probe had a hazard ratio
(HR) estimate and associated 95% confidence interval
limits. Hazard ratios below 1 indicate that the hazard
under consideration decreases as the level of the gene
increases. The proportional hazards assumption was
assessed for the final predictive models corresponding to
each survival variable based on the residuals. There was
no evidence of departure from the assumptions for all
the models reported. The association between survival
and clinical and probe expression profiles was visualized
by plotting the probability of survival predicted by the
Cox model against time. For depiction purposes, indivi-
duals were divided into low and high probe expression
groups that corresponded to the 25
th and 75
th percentile
respectively given the median expression for all other
probes in the predictive model. The survival curves were
computed based on the information used to identify the
significant gene associations. Biomarker genes resulting
from the multi-stage approach were compared to pre-
vious reports of genes associated with glioblastoma or
other cancers. The protein interaction resource at the
NCBI Gene data base [30] was used to check that bio-
markers not previously associated with cancer were also
not indirectly associated with cancer through intermedi-
ate genes.
The genes identified by the five-step approach were
compared to those resulting from a more conventional
analysis using a one-step Cox survival analysis with a
stringent cut-off (P-value < 0.0001).
Functional and Gene Network Analyses
Identification of Gene Ontology (GO) categories (mole-
cular function and biological process) and KEGG path-
ways represented among the significant genes associated
with each glioblastoma survival variable was undertaken
[31,32]. The representation of genes in the GO and
KEGG pathway classes was evaluated using Fisher’s
exact (two-tailed) test and False Discovery Rate multiple
test adjustment [33]. The relationships between the bio-
marker genes were further studied for the three
glioblastoma survival variables and significant functional
categories. The BisoGenet plug-in [34] from the Cytos-
cape software [35] was used to build and visualize the
networks for each one of the three glioblastoma survival
variables using the respective list of significant genes
from the GO categories. All the available data sources
in BisoGenet (including BIOGRID, DIP, BIND and
others) were selected to generate the interactions. To
facilitate the visualization of the networks, only interac-
tions (edges) connecting two significant genes (nodes)
directly or through an intermediate gene were depicted.
Cross-validation
The associations between gene profiles and survival
detected in this study were confirmed using a three-fold
approach. First, a leave-one-out cross-validation
(LOOCV) approach [36-38]. LOOCV is specially recom-
mended in data sets of limited size, providing an almost
unbiased estimator and identifying the same best classi-
fiers as other X-fold training-test data partitions [38,39].
Validation of the predictive survival equation and bio-
markers detected in a training data set on an indepen-
dent test data set is desirable, followed by X-fold cross-
validation on a particular data set. The representation of
all cohort factors on both the training and test sets is
necessary for unbiased evaluation of the biomarkers and
to ensure that the detected biomarkers were not a spur-
ious artifact of ignored cohort effects and for a fair eva-
luation of the training estimates. Consideration of race
is particular critical for the validation of biomarkers
detected in this study because lack of adjustment for
this cohort factor could result in the identification of
associations that are due to genetic background and not
the particular gene expression profile.
For the X-fold validation approach, the specification of
suitable training and testing data sets would have
required at least 200 patients in each data set (5 indivi-
duals × 2 races × 2 genders × 5 therapies × 2 recurrence
groups) and only 287individuals were available. The
minimum of 5 individuals per group minimizes the risk
of confounding between individual variation and cohort
variation. Use of smaller data sets would have lead to
low power and biased findings because of the ill-repre-
sentation of individuals across cohort groups. Thus, the
X-fold cross-validation could not be implemented. Like-
wise, the test of the predictive hazard equations (that
include cohort factors) on an independent data set
could not be implemented due to the lack of dataset
with comparable cohort information or adequate struc-
ture that would minimize the risk of confounding
between factors.
Accurate validation of associations between biomar-
kers and survival was attained using LOOCV discrimi-
nant analysis[40] that allows the assessment of the
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high and low hazard (low and high survival, respec-
tively). The same cohort information was used to obtain
parameter estimates and to train the predictive hazard
equations. For each survival variable, the median length
of the period considered (age at death for lifetime survi-
val; months from diagnosis to death for overall survival
and; months from diagnosis to progression/recurrence
for progression free survival) was calculated, and indivi-
duals were classified into either a high or low hazard
group based on the median. The 20% of the individuals
that had a length of period closest (higher or lower) to
the median were not considered in order to minimize
borderline cases that could affect the assessment of the
model performance. Only non-censored records were
used in the cross-validation analysis to favor unbiased
classification. All individuals except for one were used
to develop a new hazard index using the biomarkers
previously detected and the new index was used to clas-
sify the remaining individuals. This leave-one-individual-
out analysis was repeated for all individuals and the
observed and predicted affiliations of the individuals to
the high and low groups for each hazard were compared
in order to assess the correct assignment rate.
Second, in addition to LOOCV, confirmation of the
genes associated with the three glioblastoma hazards
was investigated on the independent database
REMBRANDT (REpository for Molecular BRAin Neo-
plasia DaTa) [41,42]. This database includes gene
expression and survival information on 181 individuals
diagnosed with glioblastoma. Third, a literature review
was undertaken to identify independent studies that
have reported associations between the genes associated
with survival detected in this study and glioblastoma or
other cancer types.
Results
Confirmed and Novel Biomarkers of Glioblastoma
The median length of the periods associated with life-
time, overall, and progression-free survival across and
within clinical or cohort group are presented in Table 1.
The age of the individuals at death or at the end of the
considered period ranged from 14 to 87 years with a
median age of 60 years. The median survival length was
59 years, 13 months and 7 months for lifetime, overall,
and progression-free survival, respectively.
A total of 168 significant associations between
expression profiles and glioblastoma survival (61, 47
and 60 associations for lifetime, overall, and progres-
sion-free survival, respectively) from 139 genes were
identified. Among these, 10 associations are borderline
significant (0.1 < P-value < 0.05) and are included in
the tables in support of other more significant
associations.
The vast majority of the genes associated with glio-
blastoma survival have been previously reported to be
associated with glioblastoma (35, 24, and 35 genes,
respectively) or with another cancer (10, 19, and 15
genes, respectively) and the rest (16, 4, and 10 genes,
respectively) exhibited novel associations with glioblas-
toma. Table 2 presents the distribution of genes and
probes associated with more than one hazard. Cohort-
independent and cohort-dependent associations, respec-
tively, were uncovered for lifetime (Tables 3 and 4),
overall (Tables 5 and 6), and progression-free (Tables 7
and 8) survival. Cohort-independent associations
Table 2 Genes and probes represented more than one
time within or across the glioblastoma survival events
Gene Lifetime
Survival
Overall
Survival
Progression-free
survival
Actr2 200727_s_at
200729_s_at
Akr1c3 209160_at 209160_at
App 211277_x_at
214953_s_at
Camk2b 211483_x_at
209956_s_at
Camk2g 212757_s_at 214322_at
214322_at
Cdc42 208727_s_at
208728_s_at
214230_at
Chi3l1 216546_s_at
209396_s_at
Csf1 207082_at 209716_at
E2f3 203692_s_at 203693_s_at 203693_s_at
Egfr 211551_at
211607_x_at
Fstl1 208782_at 208782_at
Hras 212983_at 212983_at
Ighg1 211908_x_at
211693_at
Il13ra1 210904_s_at 211612_s_at
Jag2 32137_at 209784_s_at
Mdm2 217373_x_at 217373_x_at
Mtap 204956_at 204956_at
Pik3r1 212240_s_at 212249_at 212239_at
Plcg1 216551_x_at 216551_x_at
Prkcb 207957_s_at
209685_s_at
Rpl37a 213459_at 213459_at
Sod2 221477_s_at 215078_at
Timp3 201148_s_at
201150_s_at
Topors 204071_s_at 204071_s_at
Tp53 211300_s_at 211300_s_at
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Page 5 of 21Table 3 Genes that have a general association (P-value < 0.05) with the lifetime glioblastoma survival
Gene Symbol Probe Identifier P-value Hazard Ratio
1 Relevant literature references
Syne1 209447_at <.0001 0.17 (0.10-0.32) [60]
O
E2f3 203692_s_at <.0001 0.26 (0.15-0.44) [28]
G
Fstl1 208782_at <.0001 0.31 (0.22-0.42) [25]
G
Ep300 213579_s_at <.0001 0.34 (0.29-0.57) [26]
G
Gigyf2 212261_at <.0001 0.39 (0.26-0.58) n/a
Topors 204071_s_at <.0001 0.41 (0.29-0.59) [26]
G
Chst4 220446_s_at 0.0989
2 0.44 (0.17-1.16) [89]
O
Sar1a 201543_s_at <.0001 0.44 (0.29-0.66) n/a
Il13ra1 210904_s_at <.0001 0.47 (0.36-0.60) [24]
G
Sod2 221477_s_at <.0001 0.47 (0.37-0.59) [25]
G
Rab15 221810_at <.0001 0.48 (0.34-0.69) n/a
Timm23 218118_s_at 0.0239 0.50 (0.27-0.91) n/a
Kcnj4 208359_s_at <.0001 0.50 (0.38-0.66) n/a
Rpl37a 213459_at 0.0023 0.51 (0.33-0.79) [90]
G
Camk2g 214322_at 0.0135 0.53 (0.32-0.88) [56]
G
Plcg1 216551_x_at 0.0068 0.55 (0.35-0.85) [26]
G
Slc43a3 213113_s_at 0.0004 0.56 (0.40-0.77) n/a
Cdc42 208727_s_at <.0001 0.57 (0.45-0.73) [26]
G
Csf1 207082_at 0.0092 0.58 (0.38-0.88) [26]
G
Ccnb2 202705_at 0.0118 0.60 (0.40-0.89) [91]
G
Tlk2 212997_s_at 0.0004 0.64 (0.49-0.82) n/a
Mtap 204956_at 0.0091 0.67 (0.49-0.91) [26]
G
Egfr 211551_at 0.0743
2 0.68 (0.45-1.04) [24]
G
Akt2 211453_s_at 0.0292 0.68 (0.48-0.96) [86]
G
Akr1c3 209160_at <.0001 0.70 (0.62-0.81) [26]
G
Tp53 211300_s_at 0.0215 0.76 (0.60-0.96) [25]
G
Igf1 209541_at 0.0183 0.76 (0.61-0.95) [26]
G
Rpl10 221989_at 0.0392 0.80 (0.64-0.99) [24]
G
Arhgef4 205109_s_at 0.0647
2 0.80 (0.64-1.01) n/a
Cdc42 214230_at 0.0554
2 0.82 (0.67-1.00) [26]
G
Chi3l1 216546_s_at 0.061 0.87 (0.75-1.00) [70]
G
Ppbp 214146_s_at 0.012 1.16 (1.03-1.30) n/a
Cdkn2a 209644_x_at 0.0003 1.18 (1.08-1.29) [92]
G
Wdr67 214061_at 0.0237 1.30 (1.03-1.63) [93]
O
Tspyl5 213122_at 0.0003 1.34 (1.14-1.56) n/a
Usf2 215737_x_at <.0001 1.42 (1.19-1.69) [94]
O
Camk2g 212757_s_at 0.0078 1.54 (1.12-2.13) [56]
G
Pik3r1 212240_s_at 0.0022 1.67 (1.20-2.32) [20]
G
Akt1 207163_s_at 0.0005 1.70 (1.26-2.30) [84]
O
Rac2 213603_s_at 0.0001 1.74 (1.31-2.31) [95]
G
Six6 207250_at <.0001 1.82 (1.45-2.28) [96]
O
Spg21 217827_s_at 0.0387 1.91 (1.03-3.52) n/a
Wdyhv1 219060_at 0.0015 1.95 (1.29-2.94) n/a
Uros 203031_s_at 0.0067 2.37 (1.27-4.42) n/a
Lin7c 219399_at 0.0002 2.40 (1.51-3.80) [97]
O
Ros1 207569_at <.0001 2.58 (1.73-3.85) [98]
O
Cdk2 204252_at <.0001 2.74 (1.78-4.21) [91]
G
Jag2 32137_at <.0001 2.78 (1.86-4.14) [24]
G
Kiaa0090 212395_s_at <.0001 2.89 (1.87-4.47) n/a
Ccnb1 214710_s_at <.0001 3.16 (2.00-4.98) [91]
G
Scn5a 207413_s_at <.0001 3.21 (1.79-5.74) n/a
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associations for lifetime, overall, and progression-free
survival, respectively.
The five-step approach was consistently superior to a
one-step Cox analysis with more stringent P-value <
0.001 on all three survival indicators. For the three vari-
ables studied; lifetime, overall, and progression-free survi-
val, the simpler approach identified 60, 71 and 67 probes
of which 19, 17, and 23 respectively overlapped with the
corresponding 61, 47, and 60 probes identified in the
five-step analyses of the three survival indicators. Of the
139 probes identified by the simpler approach and not
identified by our approach, the vast majority (123 probes
across all three variables) have not been associated with
glioblastoma and could not be confirmed.
Genes Associated with Lifetime Death Hazard
Sixty-one gene profiles, representing 55 genes, were
associated with lifetime survival. An increase in the level
of expression of 31 genes was associated with a decrease
in HR, with estimates ranging from 0.17 (Syne1)t o0 . 8 7
(Chi3l1). The changes in survival across levels of gene
expression and clinical variables for the population
under consideration were visualized using survival plots.
The decline on the probability of lifetime survival across
age (in years) for individuals with high (75
th percentile)
and low (25
th percentile) levels of Syne1 is depicted in
Figure 1. Consistent with the hazard ratio estimate (HR
= 0.17, P-value < 0.0001), the probability of survival of
individuals with high levels of Syne1 remains higher
across age. Individuals with high and low levels of Syne1
Table 4 Genes that have a cohort-dependent association (P-value < 0.05) with the lifetime glioblastoma survival
Gene Symbol Probe Identifier Clinical Cohort P-value Level of Clinical Cohort Hazard Ratio
1 Relevant literature references
Prkcb
2 207957_s_at Gender <.0001 Male 0.36 (0.24-0.55) [28]
G
Female 1.27 (0.84-1.93)
Therapy 0.0006 None 0.38 (0.25-0.60)
CRnoT 0.51 (0.36-0.73)
R 0.64 (0.46-0.88)
CRT 0.71 (0.44-1.13)
Other 0.75 (0.43-1.32)
Sox10 209843_s_at Race 0.0018 White 0.55 (0.44-0.68) [10]
G
Other 1.08 (0.72-1.62)
Egfr 211607_x_at Gender <.0001 Male 0.60 (0.50-0.72) [24]
G
Female 0.88 (0.74-1.04)
Chi3l1 209396_s_at Therapy 0.0006 CRT 1.27 (0.96-1.70) [70]
G
R 1.28 (1.07-1.52)
Other 1.31 (1.04-1.66)
CRnoT 1.53 (1.31-1.79)
None 2.42 (1.56-3.75)
C2 203052_at Gender 0.0033 Female 1.30 (1.03-1.65) n/a
Male 1.93 (1.56-2.39)
Prkcb 209685_s_at Gender <.0001 Female 1.31 (0.79-2.14) [28]
G
Male 5.21 (3.16-8.61)
n/a, No association with any type of cancer found in literature;
1 Hazard ratio estimate (95% confidence interval);
2 Interaction with a single clinical cohort factor;
G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.
Table 3 Genes that have a general association (P-value < 0.05) with the lifetime glioblastoma survival (Continued)
Col14a1 212865_s_at <.0001 3.30 (1.93-5.63) [99]
O
Hoxa10 213147_at <.0001 3.30 (1.93-5.65) [100]
O
Cdc42 208728_s_at <.0001 3.94 (2.12-7.32) [26]
G
Pdcd4 202731_at <.0001 4.68 (3.01-7.28) [26]
G
n/a, No association with any type of cancer found in literature;
1 Hazard ratio estimate (95% confidence interval);
2 Borderline significant (P-value < 0.1) included for completeness;
G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.
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Page 7 of 21Table 5 Genes that have a general association (P-value < 0.05) with the overall glioblastoma survival
Gene Symbol Probe Identifier P-value Hazard Ratio
1 Relevant literature references
Tgfa 205015_s_at 0.0002 0.12 (0.04-0.37) [28]
G
Sirpa 202895_s_at <.0001 0.24 (0.14-0.41) [26]
G
Ctbp2 210835_s_at <.0001 0.28 (0.16-0.48) [101]
O
Eef1e1 213907_at <.0001 0.37 (0.23-0.61) [102]
O
Mapk3 212046_x_at 0.0041 0.43 (0.24-0.76) [103]
O
Actr2 200727_s_at <.0001 0.43 (0.29-0.63) [24]
G
Igh@ 211637_x_at 0.0167 0.44 (0.23-0.86) n/a
Plcg1 216551_x_at <.0001 0.46 (0.31-0.68) [26]
G
Mgat3 209764_at <.0001 0.51 (0.37-0.71) [26]
G
Lrp10 201412_at 0.0041 0.60 (0.42-0.85) [24]
G
Idh1 201193_at 0.0051 0.60 (0.42-0.86) [24]
G
Tmem8b 207839_s_at <.0001 0.60 (0.46-0.77) n/a
Ccna2 203418_at <.0001 0.60 (0.49-0.75) [104]
O
Topors 204071_s_at 0.0007 0.61 (0.46-0.81) [26]
G
Rpl37a 213459_at 0.0164 0.66 (0.47-0.93) [90]
G
Mdm2 217373_x_at <.0001 0.69 (0.61-0.78) [26]
G
E2f3 203693_s_at 0.0672
2 0.75 (0.55-1.02) [28]
G
Mdfic 211675_s_at 0.0006 0.78 (0.68-0.90) [105]
O
Sod2 215078_at <.0001 0.80 (0.73-0.88) [25]
G
Akr1c3 209160_at 0.0014 0.83 (0.73-0.93) [26]
G
Thbs4 204776_at 0.0007 1.18 (1.07-1.30) [106]
O
Shc3 206330_s_at 0.0031 1.32 (1.10-1.59) [28]
G
Pik3r1 212249_at 0.0145 1.34 (1.06-1.69) [20]
G
Nkx2-5 206578_at 0.0027 1.38 (1.12-1.70) [107]
O
Hras 212983_at 0.0187 1.42 (1.06-1.90) [85]
G
Bhlhb9 213709_at 0.0192 1.42 (1.06-1.92) [108]
O
C9orf95 219147_s_at 0.0004 1.43 (1.17-1.73) [109]
O
C17orf101 219254_at 0.0085 1.46 (1.10-1.94) [110]
O
Nol3 59625_at <.0001 1.46 (1.21-1.76) [111]
O
Rangap1 212125_at 0.0225 1.47 (1.06-2.05) [26]
G
Ftsj2 222130_s_at 0.017 1.48 (1.07-2.05) [112]
O
Rrm1 201476_s_at 0.0006 1.49 (1.19-1.87) [27]
G
Jag2 209784_s_at 0.0351 1.63 (1.03-2.57) [24]
G
Tnpo1 212635_at 0.0054 1.89 (1.20-2.96) n/a
Myo7a 211103_at 0.0033 1.97 (1.25-3.10) [113]
O
Actr2 200729_s_at 0.0001 2.18 (1.47-3.23) [24]
G
Csf1 209716_at <.0001 2.33 (1.65-3.27) [26]
G
Ank1 208352_x_at 0.0003 2.38 (1.49-3.82) [24]
G
B3galnt1 211379_x_at <.0001 2.40 (1.76-3.28) [114]
O
Kras 214352_s_at 0.002 2.44 (1.38-4.31) [85]
G
Ewsr1 210012_s_at 0.0005 2.49 (1.49-4.15) [26]
G
Sec24c 202361_at <.0001 2.84 (1.76-4.60) n/a
Rpl10l 217559_at <.0001 2.95 (1.83-4.74) [115]
O
Ighg1 211908_x_at 0.0007 3.41 (1.68-6.93) [116]
O
Ighg1 211693_at 0.0007 4.33 (1.86-10.04) [116]
O
n/a, No association with any type of cancer found in literature;
1 Hazard ratio estimate (95% confidence interval);
2 Borderline significant (P-value < 0.1) included for completeness;
G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.
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Page 8 of 21have a survival probability of 50% at 69 and 52 years of
age, respectively. The opposite trend was observed in
the remaining 24 profiles that have hazard ratio esti-
mates ranging from 1.16 (Ppbp) to 4.7 (Pdcd4).
Among the genes exhibiting cohort-dependent asso-
ciations with lifetime survival (Table 4), the drop in the
probability of lifetime survival across age (in years) for
females and males with high (75
th percentile) and low
(25
th percentile) levels of Prkcb 209685_s_at is portrayed
in Figure 2. Consistent with the hazard ratio estimates
for females (HR = 1.31) and males (HR = 5.21), the
probability of survival declines faster in males with high
levels of Prkcb than females with low levels of this gene.
Genes Associated with Overall Survival
A total of 45 genes were associated with overall survival
(Tables 5 and 6). Among the cohort-independent asso-
ciations, an increase in the levels of 20 genes was asso-
ciated with a decrease in overall hazard with HR
ranging from 0.12 (Tgfa)t o0 . 8 3( Akr1c3). On the other
hand, an increase in the level of 25 genes was associated
with an increase in overall hazard with HR ranging from
1.18 (Thbs4)t o4 . 3 3( Ighg1). Among the cohort-depen-
dent associations, the hazard increased more in males
(HR = 1.29) than in females (HR = 1.02) per unit
increase in the levels of Igf2bp3.
Genes Associated with Progression-free Survival
Of the 60 probes (corresponding to 57 genes) associated
with progression-free survival, 55 had general associa-
tions and 5 had cohort-dependent associations (Tables 7
and 8). Among the genes that have cohort-independent
associations, an increase in the level of 23 genes was
associated with a decrease in HR, ranging from 0.11
(Pla2g7)t o0 . 8 5( Cd24). For the remaining 32 genes, an
increase in the level of expression was associated with
an increase in the progression-free HR ranging from
1.19 (Clec2b) to 5.28 (Paics). The decline in the progres-
sion-free survival probability across time (in months) for
individuals with high (75
th percentile) and low (25
th
percentile) levels of neuroblastoma RAS viral (v-RAS)
oncogene homolog (Nras)i sd e p i c t e di nF i g u r e3 .C o n -
sistent with the hazard ratio estimate (HR = 3.93, P-
value < 0.0001), the progression-free survival probability
falls faster in individuals with high expression levels of
Nras. With regard to the cohort-dependent association
with progression-free survival, an increase in the expres-
sion of Gdf10 was associated with a higher decrease of
the hazard ratio in males (HR = 0.37) than in females
(HR = 0.80).
Gene That Have Multiple Probes and Hazard Ratios
When multiple probes of the same gene had opposite
associations with the glioblastoma hazard (e.g. HR > 1
for probe 1 and HR < 1 for probe 2), the disagreements
were resolved by assessing the dependability of each
probe. Information on dissen t i n gp r o b e si sb r i e f l ys u m -
marized here. Probe 214322_at, of Cam2kg,w a s
o b t a i n e df r o ma no v a r yE S Ta nd thus is less reliable in
respect to brain cancer than probe 212757_s_at. Probe
208728_s_at, of Cdc42, is expected to be more reliable
than 208727_s_at because the former was obtained from
an mRNA sequence that has double the length than the
later. Probe 200729_s_at, of Actr2, corresponds to an
mRNA and is more reliable than 200727_s_at, which
corresponds to an EST from mixed tissues. Probe
210904_s_at, of Il13ra1, corresponds to a cluster of
mRNA assigned to this gene in the NCBI-Gene data-
base; meanwhile, probe 211612_s_at pertains to a single
m R N An o ta s s i g n e dt ot h eg e n ea n di sc o n s i d e r e dl e s s
reliable. Other probes include 201148_s_at of Timp3,
which corresponds to a pancreatic EST, 200727_s_at of
Actr2, which corresponds to a mixed tissue EST, and
209956_s_at of Camk2b, which corresponds to a proline
rich sequence.
Functional and Gene Network Analyses
The GO categories enriched( F D Ra d j u s t e dP - v a l u e<
0.1, ≥ 3 genes/category) among the genes associated
with each of the three glioblastoma survival variables
Table 6 Genes that have a cohort-dependent association (P-value < 0.05) with the overall glioblastoma survival
Gene Symbol Probe Identifier Clinical Cohort P-value Level of Clinical Cohort Hazard Ratio
1 Relevant literature references
Polr2d 214144_at Therapy 0.0044 Other 0.35 (0.18-0.70) [117]
O
R 0.50 (0.31-0.81)
CRT 0.68 (0.38-1.21)
None 0.77 (0.43-1.39)
CRnoT 0.93 (0.58-1.5)
Igf2bp3 203820_s_at Gender 0.0146 Female 1.02 (0.84-1.24) [118]
O
Male 1.29 (1.12-1.49)
n/a, No association with any type of cancer found in literature;
1 Hazard ratio estimate (95% confidence interval);
G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.
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Page 9 of 21Table 7 Genes that have a general association (P-value < 0.05) with the progression-free glioblastoma survival
Gene Symbol Probe Identifier P-value Hazard Ratio
1 Relevant literature references
Pla2g7 206214_at <.0001 0.11 (0.05-0.23) [119]
O
Pdgfb 216061_x_at <.0001 0.18 (0.09-0.35) [28]
G
Calm2 207243_s_at 0.0011 0.22 (0.09-0.54) [28]
G
Timp3 201148_s_at <.0001 0.26 (0.16-0.41) [26]
G
Agpat1 215535_s_at <.0001 0.27 (0.15-0.51) n/a
Ifngr1 202727_s_at <.0001 0.32 (0.19-0.53) [27]
G
Pvr 214444_s_at <.0001 0.32 (0.19-0.54) [26]
G
Ndufv1 208714_at 0.0002 0.33 (0.19-0.59) n/a
Fgfr2 211401_s_at <.0001 0.39 (0.26-0.57) [26]
G
E2f3 203693_s_at <.0001 0.42 (0.29-0.60) [28]
G
Pold2 201115_at 0.0007 0.43 (0.27-0.70) [26]
G
Calm3 200622_x_at 0.0001 0.43 (0.28-0.67) [28]
G
Tp53 211300_s_at <.0001 0.43 (0.29-0.64) [25]
G
Raf1 201244_s_at 0.0141 0.46 (0.25-0.85) [26]
G
Pknox2 219046_s_at <.0001 0.46 (0.33-0.62) [120]
O
App 214953_s_at 0.0016 0.47 (0.30-0.75) [24]
G
Fstl1 208782_at <.0001 0.47 (0.35-0.62) [25]
G
Camk2b 211483_x_at 0.0008 0.54 (0.38-0.77) [28]
G
Pten 204053_x_at 0.0003 0.60 (0.46-0.79) [26]
G
Mdm2 217373_x_at <.0001 0.66 (0.57-0.76) [26]
G
Ccnd1 208711_s_at 0.0273 0.80 (0.66-0.98) [28]
G
Hspa1a/Hspa1b 202581_at 0.0529 0.82 (0.67-1. 00) [24]
G
Cd24 208650_s_at 0.0069 0.85 (0.75-0.95) [121]
O
Clec2b 209732_at 0.0645
2 1.19 (0.99-1.44) [122]
O
Cav2 203324_s_at 0.0024 1.25 (1.08-1.44) [123]
O
Snx10 218404_at <.0001 1.34 (1.16-1.57) [124]
O
Wee1 215711_s_at 0.0083 1.37 (1.08-1.74) [27]
G
Hras 212983_at 0.0802
2 1.49 (0.95-2.33) [85]
G
Mns1 219703_at 0.0053 1.51 (1.13-2.02) n/a
Ppp1r15a 37028_at 0.011 1.54 (1.10-2.15) n/a
App 211277_x_at 0.0811
2 1.56 (0.95-2.56) [24]
G
Fadd 202535_at 0.0934
2 1.57 (0.93-2.65) [125]
O
Pik3r1 212239_at 0.018 1.60 (1.08-2.36) [20]
G
Mmp14 217279_x_at 0.0182 1.66 (1.09-2.52) [24]
G
Mtap 204956_at 0.0016 1.66 (1.21-2.27) [26]
G
Il13ra1 211612_s_at 0.0003 1.72 (1.28-2.32) [24]
G
Kcnj13 210179_at 0.0235 1.74 (1.08-2.82) [126]
O
Clip3 212358_at 0.0022 1.75 (1.22-2.50) n/a
Aanat 207225_at 0.0114 1.78 (1.14-2.79) [127]
O
Camk2g 214322_at 0.0024 1.86 (1.24-2.78) [56]
G
Prkca 215195_at 0.0005 1.90 (1.32-2.73) [28]
G
Kdm6b 41386_i_at 0.0003 2.03 (1.39-2.96) n/a
Zfy 207246_at 0.0016 2.06 (1.31-3.22) [128]
O
Smarcb1 212167_s_at 0.0004 2.06 (1.38-3.07) [26]
G
Utp20 209725_at <.0001 2.08 (1.46-2.98) n/a
Igl@ 211655_at 0.0209 2.22 (1.13-4.38) [129]
O
Atf5 204998_s_at <.0001 2.31 (1.72-3.11) [130]
G
Shox 207570_at <.0001 2.66 (1.73-4.07) [24]
G
Loc283079 215929_at 0.0071 2.73 (1.31-5.69) n/a
Ung 202330_s_at 0.0001 2.79 (1.66-4.68) [27]
G
Hnrnpd 213359_at <.0001 2.94 (1.91-4.52) n/a
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Page 10 of 21are summarized in Tables 9, 10, and 11. The functional
analysis revealed nine, two and ten biological processes
enriched among the genes associated with lifetime, over-
all, and progression-free survival respectively, and three
molecular functions enriched among the genes asso-
ciated with progression-free survival. The biological pro-
cesses of cell cycle (GO:0007049) and death
(GO:0016265) were over-represented among the genes
associated with the lifetime and progression-free survi-
vals. The gene networks for the significant genes from
the functional analyses associated with lifetime, overall,
and progression-free survival are depicted in Figures 4,
5 and 6, respectively.
Cross-validation
The performance of the gene sets as reliable prognostica-
tors of the three glioblastoma survival variables was eval-
uated. The generalization capability of the biomarker
index was tested in individuals other than those used to
develop a hazard index using a leave-one-individual-out
discriminant analysis. Individuals were predicted to
pertain to the high or low glioblastoma hazard groups for
each event using the predictive biomarker index, and the
prediction was compared to the observed classification
based on the length of the period corresponding to each
event. For both, lifetime and overall hazard, the number
of observed high and low individuals was 100, and the
number of predicted high and low individuals was 97 and
103, respectively. For the progression-free hazard, the
number of observed high and low individuals was 87 and
88, respectively, and the number of predicted high and
low individuals was 83 and 92, respectively.
Additional evaluation of the results was pursued by
comparing the genes associated with the three glioblas-
toma hazards identified in this study and the target
genes of microRNAs associated with the glioblastoma
hazard reported by Delfino et al. [43]. One third of the
sequences identified in this study are putative targets of
microRNAs associated with glioblastoma. A hypergeo-
metric test confirmed that the overlap between the
genes uncovered in this study and the target genes was
significant (P-value ≤ 0.005).
Table 8 Genes that have a cohort-dependent association (P-value < 0.05) with progression-free glioblastoma survival
Gene Symbol Probe Identifier Clinical Cohort P-value Level of Clinical Cohort Hazard Ratio
1 Relevant literature references
Gdf10 206159_at Gender 0.0317 Male 0.37 (0.23-0.60) n/a
Female 0.80 (0.45-1.42)
Vav3 218807_at Race 0.008 Other 0.41 (0.29-0.59) [81]
G
White 0.68 (0.55-0.85)
Rps20 216246_at Race 0.0003 Other 0.75 (0.39-1.44) [75]
O
White 1.83 (1.03-3.24)
Rab31 217764_s_at Race <.0001 White 1.47 (0.93-2.30) [74]
O
Other 7.72 (3.71-16.07)
Apool 213289_at Therapy 0.0026 R 1.64 (1.13-2.38) [131]
O
None 1.93 (0.63-5.98)
CRnoT 2.23 (1.55-3.20)
Other 3.86 (1.83-8.13)
CRT 4.82 (2.69-8.63)
n/a, No association with any type of cancer found in literature;
1 Hazard ratio estimate (95% confidence interval);
G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference
O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.
Table 7 Genes that have a general association (P-value < 0.05) with the progression-free glioblastoma survival
(Continued)
Camk2b 209956_s_at <.0001 3.02 (2.13-4.29) [28]
G
Timp3 201150_s_at <.0001 3.10 (1.88-5.11) [26]
G
Nras 202647_s_at <.0001 3.93 (2.60-5.95) [28]
G
Paics 214664_at <.0001 5.28 (3.13-8.91) [66]
O
n/a, No association with any type of cancer found in literature;
1 Hazard ratio estimate (95% confidence interval);
2 Borderline significant (P-value < 0.1) included for completeness;
G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.
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The data set analyzed offered a suitable representation
of the general population of glioblastoma cases. The
median overall survival was 13 months, and the prob-
abilities of survival at 12, 24, 36, 48 and 60 months
post-diagnosis were 0.59, 0.25, 0.15, 0.11 and 0.07
respectively, in this study. The median survival is similar
to that reported by Krex et al. [14], and the 60 month
survival probability is comparable to the 5-year survival
rate of 0.13 estimated for grade IV brain cancer reported
by the National Cancer Institute Surveillance Epidemiol-
ogy and End Results [44]. The similarity between the
survival rate in this study and that reported for primary
glioblastoma suggests an insignificant fraction of sec-
ondary glioblastoma samples among the samples ana-
lyzed [20].
Comparing findings against a literature review con-
firmed that the Cox survival analysis of multiple gene
expression profiles and clinical variables simultaneously
was an effective tool to detect an integrated set of gene
expression profiles exhibiting general and cohort-depen-
dent associations with the three glioblastoma survival
variables. The majority of the genes associated with life-
time, overall, and progression-free survival, in this study,
have been previously reported to be associated with glio-
blastoma (35, 24, and 35 genes, respectively) or with
another cancer (10, 19, and 15, respectively). In addition,
the multi-factor analysis and data used in this study
allowed the uncovering several novel associations
between gene profiles and glioblastoma survival. Specifi-
cally, 16, 4, and 10 previously unreported genes were
associated with lifetime, overall, and progression-free
survival, respectively in the present work. The discussion
of the findings from our study is divided into genes
associated with multiple survival variables, genes asso-
ciated with glioblastoma in a cohort-independent or
cohort-dependent manner, and further investigation of
complex associations.
Pik3r1 and E2f3 were associated with all three glio-
blastoma survival variables (Tables 2, 3, 5 and 7). The
higher glioblastoma hazards associated with higher levels
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Figure 3 Progression-free probability across post-diagnosis
months for neuroblastoma RAS viral (v-RAS) oncogene
homolog (Nras). Progression-free probability across post-diagnosis
months for individuals with Low (25
th percentile) and High (75
th
percentile) expression level of neuroblastoma RAS viral (v-RAS)
oncogene homolog (Nras). With a high hazard estimate (HR = 3.93),
the progression-free probability falls faster in individuals with high
expression levels of Nras.
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Figure 1 Probability of lifetime glioblastoma survival across
age for spectrin repeat containing, nuclear envelope 1 (Syne1).
Probability of glioblastoma survival across age for individuals with
Low (25
th percentile) and High (75
th percentile) expression level of
spectrin repeat containing, nuclear envelope 1 (Syne1). With a lower
hazard estimate (HR = 0.17), the probability of survival of individuals
with high levels of Syne1 remains higher across age.
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Figure 2 Probability of lifetime glioblastoma survival across
age in females and males for protein kinase, C beta (Prkcb).
Probability of glioblastoma survival across age for Females and
Males with Low (25
th percentile) and High (75
th percentile)
expression level of protein kinase, C beta (Prkcb). Consistent with
the hazard ratio estimates for females (HR = 1.31) and males (HR =
5.21), the probability of survival in individuals with high levels of
Prkcb declines before than in individuals with lower levels of Prkcb.
Due to the significant interaction between the expression of Prkcb
and gender, the probability of survival for females with high level of
the gene declines faster than the probability of survival for males
with low level of the gene.
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vious work showing that over-expression of this gene
plays a role in the activation of the PI3K/Akt pathway
resulting in cell proliferation and tumor invasion [45].
Likewise, a link between E2f3 and glioblastoma has
been reported [28,46]. Among the 15 genes associated
with two glioblastoma events (Table 2), Akr1c3, Csf1,
Jag2, Plcg1, Rpl37a, Sod2,a n dTopors were associated
with lifetime and overall survival (Tables 3 and 5). Jag2
has been associated with adenomas [47], pancreatic
[48] and breast cancer [49], Rpl37a with nasopharyn-
geal carcinoma cell lines [50], and the rest with glio-
blastoma [26,51-54]. The consistent findings across
both glioblastoma survival events suggest that these
genes may have specific roles in death. Likewise, the
association between Hras and overall and progression-
free survival (Tables 2, 5 and 7), is consistent with pre-
vious glioblastoma studies [55] and suggests that this
gene may have a role in aggressive glioblastoma
growth. Fstl1, Mtap, Tp53, Camk2g 214322_at, and
Il13ra1 probe 210904_s_at, were associated with life-
time and progression-free survival (Tables 2, 3 and 7)
and these associations are supported by previous stu-
dies [20,24,25,28,56-58].
Most genes (lifetime survival, 55 out of 61 genes; over-
all survival, 45 out of 47 genes; and progression-free
survival, 55 out of 60 genes) were associated with survi-
val in a general or cohort-independent manner. The
most extreme cohort-independent changes in lifetime
survival were observed in Syne1 (HR = 0.17) and Pdcd4
(HR = 4.68), and the former profile has been found in
lung [59], ovarian [60], colon, and breast cancers [61];
while, the second has been associated with glioma [62].
The most extreme cohort-independent changes in over-
all survival were observed in Ighg1 (HR = 4.33) and Tgfa
(HR = 0.12), and the former trend has been found in
cancer cell lines [63]; meanwhile the later is present in
the KEGG glioma pathway [28]. Lastly, the genes that
presented extreme hazard ratio values and general asso-
ciation with progression-free survival are Pla2g7 (HR =
0.11) and Paics (HR = 5.28). The Pla2g7 and Paics
trends identified in this study are consistent with those
reported for breast cancer in mice [64] and in non-
glioma types of cancer [65,66], respectively.
Table 10 Gene Ontology categories enriched among the genes associated with overall glioblastoma survival
Gene
Ontology
Level Term P-
value
FDR Adjusted
P-value
Number of
genes
Genes
Biological
process
4 anatomical structure morphogenesis
(GO:0009653)
5.39E-
05
1.16E-02 9 Nkx2-5, Csf1, Mapk3, Tgfa, Thbs4, Jag2,
Igf2bp3, Myo7a, Hras
6 organ morphogenesis (GO:0009887) 3.83E-
06
2.40E-03 7 Nkx2-5, Csf1, Mapk3, Tgfa, Jag2, Myo7a, Hras
1 Only GO categories with False Discovery Rate (FDR) adjusted P-value < 0.1 and represented by three or more genes.
Table 9 Gene Ontology categories enriched among the genes associated with lifetime glioblastoma survival
1
Gene
Ontology
Level Term P-
value
FDR
adjusted P-
value
Number
of genes
Genes
Biological
process
3 aging (GO:0007568) 2.13E-
05
1.62E-03 3 Pdcd4, Cdkn2a, Tp53
regulation of biological
process (GO:0050789)
2.77E-
04
1.50E-02 20 Usf2, Cdkn2a, Ccnb2, Akt2, Tp53, Cdc42, Six6, Jag2, Lin7c, Pdcd4,
Csf1, Topors, Spg21, Akt1, Egfr, Sox10, C2, Scn5a, Arhgef4, Cdk2
protein localization
(GO:0008104)
1.49E-
03
3.77E-02 7 Topors, Akt1, Sar1a, Egfr, Timm23, Tp53, Lin7c
cell division (GO:0051301) 2.04E-
03
3.88E-02 3 Ccnb2, Cdc42, Cdk2
cell cycle (GO:0007049) 3.75E-
03
5.14E-02 7 Pdcd4, Egfr, Cdk2, Cdkn2a, Ccnb2, Tp53, Jag2
nitrogen compound
metabolic process
(GO:0006807)
4.06E-
03
5.14E-02 4 Chst4, Akt1, Egfr, Chi3l1
cell proliferation
(GO:0008283)
8.32E-
03
8.99E-02 6 Csf1, Topors, Egfr, Cdk2, Tp53, Jag2
death (GO:0016265) 9.46E-
03
8.99E-02 6 Akt1, Cdkn2a, Tp53, Jag2, Pdcd4, Topors
4 cell aging (GO:0007569) 4.38E-
06
9.42E-04 3 Pdcd4, Cdkn2a, Tp53
1 Only GO categories with False Discovery Rate (FDR) adjusted P-value < 0.1 and represented by three or more genes.
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Page 13 of 21Several genes (lifetime survival, 6 out of 61 genes;
overall survival, 2 out of 47 genes; and progression-free
s u r v i v a l ,5o u to f6 0g e n e s )w ere associated with glio-
blastoma survival in a cohort-dependent manner. These
findings indicate that effective use of these genes in
prognostic indices or in therapy development must con-
sider the personal characteristics of the individual.
Higher levels of C2 and Prkcb (probe 209685_s_at) were
associated with a higher lifetime death hazard in males
(HR = 1.93 and 5.22, respectively) than in females (HR
= 1.30 and 1.31, respectively) and the profile of the lat-
ter gene has been observed in colon cancer cell lines
[67]. The lifetime hazard estimate decreased with
increased levels of Sox10 in Caucasian individuals (HR =
0.55) compared to non-Caucasian individuals, and this
pattern is concordant with broad distribution of Sox10
in high grade gliomas [68]. Increases in the level of
Chi3l1 were associated with significant increases in life-
time hazard estimates across all therapies with the high-
est hazard ratio observed in individuals receiving no
therapy (None, HR = 2.42). This trend is consistent with
reports that Chi3l1/Ykl-40 was highly overexpressed in
glioblastoma relative to nonneoplastic brain [69] and
that Ykl-40 is associated with poorer response to radia-
tion and shorter lifetime survival in glioblastoma [70].
Males (HR = 0.36) and individuals receiving no therapy
(HR = 0.38) have the lowest hazard ratio per increase in
Prkcb (probe 207957_s_at). These trends are consistent
with those reported for other cancer types [67] and with
observations of protein kinase C activation in gamma-
irradiated proliferating and confluent human lung fibro-
blast cells [71].
The cohort-dependent associations between overall
survival and both Polr2d and Igf2bp3 have been
observed in colorectal cancer [72] and glioblastoma [73],
respectively. Three genes (Rab31, Rps20 and Apool)
exhibited a cohort-dependent association with overall
survival that is consistent with previously reported
trends [74-76]. Lastly, the gender-dependent association
between Gdf10 and progression-free survival is in agree-
ment with reports of copy number loss of Gdf10 in
mesothelioma [77].
Further analyses of the association between individual
genes (with or without clinical variables) and hazards
were undertaken when the trend estimated from the
multi-gene index was opposite to that previously
reported. Nine genes and survival events were re-ana-
lyzed individually and compared to previous reports
including: E2f3 and all three survival variables [28,46],
Egfr and lifetime survival [78], Cfs1 and lifetime survival,
Mdm2 with overall hazard [79], Fstl1 and lifetime and
progression-free survival [25], Mtap and progression-
Table 11 Gene Ontology categories enriched among the genes associated with progression-free survival
Gene
Ontology
Level Term P-value FDR Adjusted
P-value
Number of
genes
Genes
Biological
process
3 cell cycle (GO:0007049) 3.89E-06 2.96E-04 11 Hras, Ppp1r15a, App, Calm2, Atf5, Pten, E2f3,
Wee1, Tp53, Ccnd1, Nras
death (GO:0016265) 3.18E-04 1.21E-02 9
2 App, Raf1, Atf5, Pten, Fadd, Hspa1a/Hspa1b,
Tp53, Ppp1r15a
response to biotic stimulus
(GO:0009607)
4.11E-03 5.13E-02 6
2 Fadd, Hspa1a/Hspa1b, Clec2b, Ccnd1, Ifngr1
response to abiotic stimulus
(GO:0009628)
8.17E-03 6.90E-02 6
2 Fadd, Hspa1a/Hspa1b, Clec2b, Ccnd1, Ifngr1
4 cell cycle process (GO:0022402) 4.26E-06 9.16E-04 10 App, Atf5, Pten, E2f3, Wee1, Tp53, Ccnd1, Nras,
Hras, Ppp1r15a
5 regulation of cell cycle (GO:0051726) 2.90E-07 1.22E-04 10 Wee1, Tp53, Ccnd1, App, Nras, Hras, Ppp1r15a,
Atf5, Pten, E2f3
6 regulation of progression through cell
cycle (GO:0000074)
1.47E-07 9.24E-05 10 Tp53, Ccnd1, Nras, Hras, Ppp1r15a, App, Atf5,
Pten, E2f3, Wee1
cell death (GO:0008219) 2.13E-04 6.18E-02 9
2 Ppp1r15a, App, Raf1, Atf5, Pten, Fadd, Hspa1a/
Hspa1b, Tp53
7 programmed cell death (GO:0012501) 1.19E-04 2.23E-02 9
2 Ppp1r15a, App, Raf1, Atf5, Pten, Fadd, Hspa1a/
Hspa1b, Tp53
8 apoptosis (GO:0006915) 1.41E-04 5.21E-02 9
2 Ppp1r15a, App, Raf1, Atf5, Pten, Fadd, Hspa1a/
Hspa1b, Tp53
Molecular
function
3 pattern binding (GO:0001871) 3.26E-04 3.55E-02 3 Fstl1, App, Fgfr2
carbohydrate binding (GO:0030246) 1.26E-03 6.89E-02 4 Fstl1, App, Fgfr2, Clec2b
4 polysaccharide binding (GO:0030247) 3.01E-04 8.70E-02 3 Fstl1, App, Fgfr2
1 Only GO categories with False Discovery Rate (FDR) adjusted P-value < 0.1 and represented by three or more genes;
2 Although Hspa1a/Hspa1b are represented by the same probe (202581_at), these isoforms are counted as two units.
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Page 14 of 21free hazard [57], Pdcd4 and lifetime survival [62], Tgfa
and overall survival [80], and race-dependent Vav3 and
overall survival [81]. In the first six cases, the considera-
tion of the gene alone as predictor of glioblastoma survi-
val as standard in previous reports resulted in non-
significant associations, in this study. These results indi-
cate that the accurate identification of biomarkers and
precise characterization of the trend requires the study
of the genes in concert with other genes in a systems
biology framework, such as the approach implemented,
in this study. Re-analysis of Pdcd4 and Vav3 confirmed
the significant trend detected in the multi-gene analysis,
suggesting that further studies are needed to precisely
characterize the trend.
The LOOCV confirmed the adequacy of the set of
genes and clinical variables identified to predict the glio-
blastoma hazards. The minor differences between the
observed and predicted numbers in each group may be
due to the discretization of the survival length into high
and low groups required by the discriminant analysis;
whereas, the Cox survival analysis models continuous
time to the glioblastoma event. The significant number
of genes prognostic of glioblastoma survival identified in
this study that are also targets of microRNAs associated
with glioblastoma [43] further confirms our results.
In addition to literature review and LOOCV, the gene-
survival associations detected in this study were con-
firmed using the information from the REMBRANDT
database. The associations between survival and the 10
gene probes with the most extreme hazard ratio esti-
mate for each of the three survival variables studied that
did not interact with cohort variables (Tables 3, 5, 7)
were investigated in REMBRANDT. The query was per-
formed using the Kaplan-Meier survival plot for Gene
Expression Data. Of these, eight genes had the same sig-
nificant trend observed in our study (Syne1, Gigyf2/
Tnrc15, Scn5a, Hoxa10, Pdcd4, Tgfa, Pla2g7 and
Agpat1), two did not have information on the
REMBRANDT database (Ighg1 and Hnrnpd), Fstl1 had
an opposite trend than the one observed in our study
Figure 4 Gene network from the functional analysis of lifetime glioblastoma survival. Interaction between the significant genes from the
functional analysis of lifetime glioblastoma death. The gold edges represent protein interactions whereas the red edges represent interaction of
the HNF4A protein with the DNA of the genes Pdcd4, Sox10 and Timm23. Of the 24 genes from Table 9, 18 (pink nodes) interact among each
other in a direct way or through an intermediate gene (blue nodes).
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Page 15 of 21and in previous independent studies (Table 3) and most
of the remaining genes, although non-significant, had
the same trend observed in our analysis. The latter
results are consistent with the simpler analytical
approach based on Kaplan-Meier curves available in
REMBRANDT, when compared to the more flexible
Cox survival analysis usedi no u rs t u d y .T h eK a p l a n -
Meier approach relies on non-parametric rank-based
test to compare the survival between individuals with
high and low gene expression. These groups are
obtained by setting up an arbitrary expression threshold.
Non-parametric rank-based approaches tend to have
lower power to detect significant variation than semi-
and parametric approaches such as the Cox survival
analysis. In addition, the Kaplan-Meier analysis only
allows the consideration of one explanatory variable at a
time, and this variable has to be discrete (thus, the rea-
son for comparing high and low expression groups in
REMBRANDT). This approach does not allow consider-
ing multiple continuous covariates (i.e. gene expression)
and factors (e.g. race, gender, therapy and progression)
or interactions simultaneously. The Cox-survival analysis
implemented in our study allows the simultaneous con-
sideration of multiple factors (such as possible popula-
tion stratification due to race), covariates (e.g. other
gene expression profiles) and interactions, and it does
not require the discretization of the gene expression
values that could result in potential loss of information.
Thus, the Cox approach used in our study is able to
capture the association between continuous gene
expression values and survival conditional on all other
model terms and is able to detect associations that are
likely not to reach statistical significance using the
Kaplan-Meier comparison of survival between high and
low gene expression groups.
Among the GO categories, 19 biological processes and
three molecular functions were over-represented (FDR
adjusted P-value < 0.1, ≥ 3 genes per category) in the
genes associated with the three glioblastoma events stu-
died (Tables 9, 10 and 11). Two biological processes,
cell cycle (GO:0007049) and death (GO:0016265), were
over-represented in the lifetime and progression-free
survival (Tables 9 and 11), and several biological pro-
cesses have been previously associated with glioblastoma
[17,62,68,70,79,82-86]. These processes included: aging,
morphogenesis, cell cycle and proliferation, and death
for lifetime survival; morphogenesis for overall survival;
and cell cycle, death and recognition, death, response to
biotic and abiotic stimuli, programmed cell death, and
apoptosis for progression-free survival.
The study of complementary glioblastoma survival vari-
ables allowed to confirm that the gene profiles associated
with lifetime survival resulting in the enriched functional
category of aging are clearly associated with cancer initia-
tion and progression and are not a simply reflection of the
natural aging process. Two results confirm that the bio-
markers are not mere confounding with aging. First, the
genes in the GO terms “aging (GO:0007568)” and “cell
aging (GO:0007569)”, Pdcd4, Cdkn2a, and Tp53,h a v ea l l
been associated with GBM in previous independent stu-
dies (Table 3). In addition, Tp53 was associated with pro-
gression-free survival (Table 7). Second, other functional
terms enriched among the genes associated with lifetime
glioblastoma survival were also identified on the other
glioblastoma survival variables studied. The biological pro-
cesses of cell death and cell cycle were enriched both for
lifetime and progression-free survival.
The biological processes, molecular functions and
gene networks particular to a glioblastoma survival
event offered insights into the processes particular to
the initiation and progression of this cancer. For
instance, eight biological processes associated with life-
time survival were level 3, and one was level 4, indicat-
ing that the differentially expressed genes associated
Figure 5 Gene network from the functional analysis of overall
glioblastoma survival. Relationship between the significant genes
from the functional analysis of overall survival. Of the nine genes
from Table 10, four (pink nodes) interact among each other in a
direct way or through an intermediate gene (blue nodes).
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biological mechanisms. The interconnection between
the genes pertaining to aging further confirms the sig-
nificance of this gene network on lifetime survival (Fig-
ure 4). Although only two biological processes were
associated with overall survival, these processes corre-
spond to levels 4 and 6. This result indicates that the
genes associated with overall survival correspond to
more specific mechanisms. Moreover, both biological
processes are related to generation and organization of
anatomical structures, such as organs, and this finding
may be associated to the dispersion and development of
malignant cells after diagnosis and resection. The close
relationship between biomarker genes in this network
supports this finding (Figure 5). Albeit the study of pro-
gression-free survival encompassed a shorter period
than lifetime and overall survival, the functional analysis
showed several biological processes and molecular func-
tions over-represented among the genes associated with
this survival. Four of the biological processes are from
level 6 to 8, indicating that specific gene networks and
roles are associated with progression-free survival. The
biological processes associated with progression-free
survival include regulation of progression through cell
cycle, programmed cell death, and apoptosis. Extensive
relationships between the biomarker genes in the cell
cycle were identified further, supporting the major role
of this network on glioblastoma progression (Figure 6).
In addition, three molecular functions were enriched
among the genes associated with progression-free survi-
val. Therefore, many biological and molecular events
occur in the period between the diagnosis of malignancy
and progression or recurrence, probably due to response
to numerous treatments, surgery, and cancer progres-
sion. Two genes were highly represented across the
categories (Tables 9 to 11). Tp53 has an important role
as a tumor repressor [83], and App is highly expressed
in individuals with short-term glioblastoma survival [24].
Conclusions
An innovative approach to identify simultaneously mul-
tiple biomarkers of lifetime, overall and progression-free
Figure 6 Gene network from the functional analysis of progression-free survival. Relationship between the significant genes from the
functional analysis of progression-free survival. Of the 19 genes from Table 11, 17 (pink nodes) interact among each other in a direct way or
through an intermediate gene (blue nodes).
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Page 17 of 21glioblastoma survival in a systems biology framework
was presented. Furthermore, the inclusion of clinical
information allowed the uncovering of general and indi-
vidualized associations between gene expression profiles
and three complementary survival metrics. This study
demonstrated the pre-eminence of developing multi-
gene prognostic indices of glioblastoma survival through
the integration of variable selection and survival models
relative to the simple-yet- simplistic single-gene analysis.
Known biomarker gene profiles were confirmed, and
new general and clinical-dependent gene profiles were
uncovered. The present study looked at glioblastoma in
general and complements work on the identification of
genes associated with specific glioblastoma types
[42,87,88]. Empirically confirmed findings will be the
basis for improved prognostic tools and individualized
treatments that improve the survival and quality of life
of individuals suffering glioblastoma multiforme.
Additional material
Additional file 1: List of genes associated in glioblastoma from the
literatureTable containing the list of 174 genes previously reported in
the literature.
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